ID29187A - Terapi kombinasi alfa internferon-ribavirin untuk memusnahkan hcv-rna yang dapat ditemukan pada pasien-pasien yang mengalami infeksi hepatitis c kronis - Google Patents

Terapi kombinasi alfa internferon-ribavirin untuk memusnahkan hcv-rna yang dapat ditemukan pada pasien-pasien yang mengalami infeksi hepatitis c kronis

Info

Publication number
ID29187A
ID29187A IDW20010844A ID20010844A ID29187A ID 29187 A ID29187 A ID 29187A ID W20010844 A IDW20010844 A ID W20010844A ID 20010844 A ID20010844 A ID 20010844A ID 29187 A ID29187 A ID 29187A
Authority
ID
Indonesia
Prior art keywords
rna
combination therapy
chronic hepatitis
internferon
alfa
Prior art date
Application number
IDW20010844A
Other languages
English (en)
Indonesian (id)
Inventor
Ashit K Ganguly
Jinping Mccormick
Raymond G Lovey
Frank Bennett
Anil K Saksena
Viyyoor M Girijavallabhan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/348,534 external-priority patent/US6277830B1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of ID29187A publication Critical patent/ID29187A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
IDW20010844A 1998-10-16 1999-10-14 Terapi kombinasi alfa internferon-ribavirin untuk memusnahkan hcv-rna yang dapat ditemukan pada pasien-pasien yang mengalami infeksi hepatitis c kronis ID29187A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17405998A 1998-10-16 1998-10-16
US09/348,534 US6277830B1 (en) 1998-10-16 1999-07-07 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon

Publications (1)

Publication Number Publication Date
ID29187A true ID29187A (id) 2001-08-09

Family

ID=26869824

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010844A ID29187A (id) 1998-10-16 1999-10-14 Terapi kombinasi alfa internferon-ribavirin untuk memusnahkan hcv-rna yang dapat ditemukan pada pasien-pasien yang mengalami infeksi hepatitis c kronis

Country Status (20)

Country Link
EP (1) EP1121369B1 (de)
JP (1) JP2002527522A (de)
CN (1) CN1330658A (de)
AT (1) ATE284408T1 (de)
AU (1) AU762395B2 (de)
BR (1) BR9915546A (de)
CA (1) CA2346447C (de)
CZ (1) CZ20011130A3 (de)
DE (1) DE69922529T2 (de)
ES (1) ES2229820T3 (de)
HU (1) HUP0200447A2 (de)
ID (1) ID29187A (de)
IL (1) IL142423A0 (de)
NO (1) NO20011789L (de)
NZ (1) NZ510811A (de)
PL (1) PL347268A1 (de)
RU (1) RU2001113268A (de)
SK (1) SK4742001A3 (de)
TR (1) TR200101085T2 (de)
WO (1) WO2000023454A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001255495A1 (en) 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
WO2004084796A2 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
WO2005016370A1 (en) * 2003-08-13 2005-02-24 Howard J. Smith & Associates Pty Ltd Method of treating viral infections
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
CA2606106A1 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
JPWO2009028573A1 (ja) 2007-08-27 2010-12-09 国立大学法人名古屋大学 血液凝固障害におけるリバビリンの利用
US20110045535A1 (en) 2007-08-27 2011-02-24 National University Corporation Nagoya University Activator for Blood Coagulation Factor VII Promoter and Utilization of the Same
WO2011151667A1 (en) 2010-06-02 2011-12-08 Adbula Kurkayev Antiviral compositions
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CA2811203C (en) 2011-10-21 2015-05-05 Abbvie Inc. Methods for treating hcv
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
WO2018035380A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
CN107513055B (zh) * 2017-08-11 2018-06-22 广东昊邦医药健康有限责任公司 一种利巴韦林衍生化合物及其药物组合物
US20240325419A1 (en) 2022-05-05 2024-10-03 Abdula Kurkayev Pharmaceutical composition for restoring physiological processes and cells of organism

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1482736A (en) * 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) * 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
AU735438B2 (en) * 1996-11-12 2001-07-05 Medivir Ab Nucleosides

Also Published As

Publication number Publication date
ES2229820T3 (es) 2005-04-16
JP2002527522A (ja) 2002-08-27
BR9915546A (pt) 2001-08-14
AU1197500A (en) 2000-05-08
SK4742001A3 (en) 2001-11-06
IL142423A0 (en) 2002-03-10
EP1121369A1 (de) 2001-08-08
RU2001113268A (ru) 2003-09-27
TR200101085T2 (tr) 2001-08-21
NZ510811A (en) 2003-06-30
CN1330658A (zh) 2002-01-09
DE69922529D1 (de) 2005-01-13
NO20011789L (no) 2001-06-11
CA2346447C (en) 2006-01-31
AU762395B2 (en) 2003-06-26
ATE284408T1 (de) 2004-12-15
WO2000023454A1 (en) 2000-04-27
DE69922529T2 (de) 2005-12-15
CA2346447A1 (en) 2000-04-27
PL347268A1 (en) 2002-03-25
HUP0200447A2 (en) 2002-06-29
CZ20011130A3 (cs) 2001-08-15
EP1121369B1 (de) 2004-12-08
NO20011789D0 (no) 2001-04-09

Similar Documents

Publication Publication Date Title
MY129244A (en) Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection.
IL142423A0 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
HK1052878A1 (zh) 利巴传林-聚乙二醇化干扰素α：丙型肝炎病毒的联合治疗
EP0903148A3 (de) Kombinationtherapie für Entfernen von nachweisbare HCV-RNA im Patienten mit chronische Hepatitis C-Infektion
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
NZ309217A (en) Ribavirin and interferon alpha for the treatment of hepatitis C
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
PT880350E (pt) Tratamento de esclerose multipla
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
PT1039884E (pt) Metodo para a prevencao e tratamento do miocardio aturdido
ATE184788T1 (de) Idebenone-haltige zusammensetzungen zur behandlung von m. alzheimer
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
DK0671918T3 (da) Præparater indeholdende acyclovir-lignende forbindelser og 2-vinylsubstituerede nucleosidanaloge til behandling af virusinfektioner
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
NO960866D0 (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler
UA37528A (uk) Спосіб профілактики післяопераційних ускладнень у дітей після тонзилектомії
TH52792A3 (th) การรักษาแบบการรวมกันของไรบาวิรีน-อินเตอร์เฟอรอนอัลฟา เพื่อทำลาย hcv-rna ที่ตรวจหาได้ในผู้ป่วยที่มีการติดเชื้อตับอักเสบ c เรื้อรัง